Insider Subir Dutt plans XMTR sale of 2,500 Xometry shares

Rhea-AI Filing Summary

Xometry (XMTR) insider Subir Dutt has filed a Form 144 indicating an intention to sell 2,500 shares of common stock. The planned sale through UBS Financial Services on Nasdaq has an aggregate market value of $175,000, with Xometry reporting 49,772,345 common shares outstanding.

Dutt acquired these 2,500 shares as RSUs from the issuer on April 1, 2025. Over the past three months, he has already sold 425, 2,075, and 3,929 common shares on earlier dates, for gross proceeds of $25,643.61, $124,500.00, and $257,563.94, respectively.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc. 11 Madison Avenue 4th Floor New York NY 10010	2500	175000.00	49772345	02/09/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	04/01/2025	RSU	Issuer			2500	04/01/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Subir Dutt 6116 Executive Boulevard Suite 800 North Bethesda MD 20852	Common	11/17/2025	425	25643.61
Subir Dutt 6116 Executive Boulevard Suite 800 North Bethesda MD 20852	Common	11/19/2025	2075	124500.00
Subir Dutt 6116 Executive Boulevard Suite 800 North Bethesda MD 20852	Common	01/05/2026	3929	257563.94

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What insider transaction does the XMTR Form 144 disclose?

The Form 144 discloses that insider Subir Dutt plans to sell 2,500 shares of Xometry common stock. The planned sale has an aggregate market value of $175,000 and is expected to be executed on the Nasdaq market through UBS Financial Services.

How many Xometry (XMTR) shares has the insider recently sold?

Over the past three months, insider Subir Dutt sold three blocks of Xometry common shares: 425 shares on November 17, 2025, 2,075 shares on November 19, 2025, and 3,929 shares on January 5, 2026, generating combined gross proceeds over $400,000.

How did the Xometry (XMTR) insider acquire the 2,500 shares being sold?

The 2,500 Xometry common shares being registered for sale were acquired on April 1, 2025 through an RSU (restricted stock unit) grant from the issuer. The filing lists the issuer as the source and shows the acquisition and payment dates both as April 1, 2025.

Which broker and exchange are involved in the planned XMTR share sale?

The planned sale of 2,500 Xometry common shares will be handled by UBS Financial Services Inc., located at 11 Madison Avenue in New York. The filing states that the shares are expected to be sold on the Nasdaq securities exchange.

How many Xometry (XMTR) shares are outstanding in this Form 144?

The Form 144 reports that Xometry has 49,772,345 common shares outstanding. This figure provides context for the planned sale of 2,500 shares by insider Subir Dutt, indicating the overall size of the company’s equity base at the time of the notice.

What representation does the Xometry insider make in the Form 144 filing?

By signing the notice, the person for whose account the securities are to be sold represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed, as required under the Form 144 instructions.